Page 16 - Chumakov News Today

Chumakov center submits its COVID-19 vaccine dossier for WHO prequalification According to the Center’s director Aidar Ishmukhametov, prequalification is a long process, it is too early to talk about timing MOSCOW, April 28. /TASS/. The Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products of the Russian Academy of Sciences has submitted a vaccine dossier to the World Health Organization (WHO) for prequalification of its CoviVac vaccine, the Cent...

Some 12.1 mln have received their first vaccine dose, Deputy Prime Minister Tatyana Golikova said MOSCOW, April 27. /TASS/. More than 12 mln Russians have received at least one dose of a coronavirus vaccine, and 7.7 mln have been fully vaccinated, Deputy Prime Minister Tatyana Golikova said at a meeting of the Council of Legislators of the Russian Federation on Tuesday. "As many as 12.1 mln of our fellow citizens have received their first vaccine dose and 7.7 mln have been fully vaccinated," sh...

MOSCOW, April 27. /TASS/. Russia’s Chumakov Center can manufacture up to one million sets of its CoviVac coronavirus vaccine doses in three months, Aidar Ishmukhametov, director general of the center and a corresponding member of the Russian Academy of Sciences, told TASS on Tuesday. "Our center has a well-oiled production of vaccines. In the first quarter of this year, we manufactured as many vaccines as we had planned. We can make up to one million CoviVac vaccine sets quarterly," he said. ...

On March 25, the Chumakov Center launched production of the third Russian COVID-19 vaccine dubbed CoviVac

By today, three anti-coronavirus vaccines have been registered in Russia © Peter Kovalev/TASS MOSCOW, April 20. /TASS/. /TASS/. It will be possible to vaccinate 70% of Russia’s population against the coronavirus infection by November 2021, Alexander Gintsburg, director of the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Health Ministry, the Sputnik V vaccine developer, said on Tuesday. "If the entire global immune-biological industry is mobilized to ma...

CoviVac vaccine can be effective against all coronavirus mutations — developer As of April 16, more than 190 cases of the British coronavirus strain and more than 20 cases of the South African strain were registered in Russia MOSCOW, April 20. /TASS/. The CoviVac coronavirus vaccine developed by the Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products at the Russian Academy of Sciences can be effective against all currently known coronavirus mut...

According to Mikhail Murashko, vaccination will help avoid not only infection but also serious complications © Alexander Astafiev/POOL/TASS MOSCOW, April 10. /TASS/. Covid-19 causes twice as many complications as seasonal influenza and other respiratory diseases, so, vaccination will help avoid not only infection but also serious complications, Russian Health Minister Mikhail Murashko said on Saturday. "The novel coronavirus infection has practically twice as many complications, neurological...

EpiVacCorona effective against British, South African coronavirus strains — expert The researcher said should new coronavirus strains emerge, it would be possible to promptly modify the vaccines accordingly © Donat Sorokin/TASS MOSCOW, April 7. /TASS/. Russia’s vaccine EpiVacCorona is effective against the British and South African mutations of the novel coronavirus, the chief of Vectors Yekaterinburg Research Institute of Viral Infections, Alexander Semyonov said on the Vesti FM radi...

Kremlin says number of those willing to get vaccinated against Covid-19 growing rapidly The Kremlin spokesman said that it might be a result of a quite vigorous advertising campaign in the mass media © Sergei Bobylev/TASS MOSCOW, April 5. /TASS/. The number of Russians willing to get vaccinated against the coronavirus infection is growing quite rapidly, Russian president’s press secretary Dmitry Peskov said on Monday. Read also "Indeed, the number of those willing to get vaccinated is grow...

Email Johnson & Johnson says it has expanded its phase 2a clinical trial to include young people age 12 to 17. The FDA has also said that Moderna’s vaccine can be stored at room temperature for up to a day and that the company can include extra doses in its vials. These changes could help speed up distribution of the vaccine. COVID-19 vaccines have reached consumers in record time. Though the process can typically take 10 to 15 years, the U.S. Food and Drug Administration has granted emergenc...